Evidence-based guidelines for the management of hypertension in children with chronic kidney disease.
Hypertension is common in children with chronic kidney disease and early evidence suggests that it is a modifiable risk factor for renal and cardiovascular outcomes. Recommendations for blood pressure management in children with chronic kidney disease can be found in various clinical practice guidelines including the 4th Task Force Report, the European Society of Hypertension pediatric recommendations, and the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for the management of blood pressure in chronic kidney disease. Unfortunately, as pediatric trial evidence is limited, there are discrepancies in the recommendations that may lead to inconsistent clinical care and practice variation. This article reviews the strength of evidence behind each of the clinical practice guideline recommendations regarding blood pressure assessment, treatment targets, and first-line antihypertensive medications. The benefits and cautions of use of clinical practice guidelines are described with emphasis on the importance of reading beyond the summary statements.
Division of Nephrology, Department of Pediatrics, University of British Columbia, BC Children's Hospital, 4480 Oak Street, Vancouver, BC, V6H 3V4, Canada. jdionne@cw.bc.ca.
Janis M
JM
Dionne
D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002648:Child; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000209:etiology; D017410:Practice Guidelines as Topic / Q000592:standards*; D051436:Renal Insufficiency, Chronic / Q000150:complications*
D000959:Antihypertensive Agents
Ambulatory blood pressure monitoring; Angiotensin receptor blocker; Angiotensin-converting enzyme inhibitor; Clinic blood pressure; Clinical practice guideline; Target blood pressure; Treatment